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A B S T R A C T
Objective: To determine whether diabetes and sex were factors associated with ambulatory function, en-
dothelial cell inﬂammation, oxidative stress, and apoptosis, andwith circulating biomarkers of inﬂammation
and antioxidant capacity in patients with peripheral artery disease (PAD) and claudication.
Materials/Methods: Ambulatory function of 180 symptomatic men and women with PAD was assessed
during a graded maximal treadmill test, 6-minute walk test, and 4-meter walk test. Patients were further
characterized on endothelial effects of circulating factors present in the sera using a cell culture-based
bioassay on primary human arterial endothelial cells, and on circulating inﬂammatory and vascular
biomarkers.
Results: Men and women with diabetes had greater prevalence (p = 0.007 and p = 0.015, respectively)
of coronary artery disease (CAD) than patients without diabetes. To assure that this difference did not
inﬂuence planned comparisons, the data set was stratiﬁed on CAD. Diabetic men with CAD had a lower
peak walking time (PWT) during the treadmill test and a slower 4-meter gait speed compared to non-
diabetic men with CAD (p < 0.05). Diabetic women with CAD had a lower PWT compared to their non-
diabetic counterparts (p < 0.01). Additionally, diabetic men with CAD had higher pigment epithelium-
derived factor (p < 0.05) than their non-diabetic counterparts, and diabetic women with CAD had higher
leptin (p < 0.01) and interleukin-8 levels (p < 0.05).
Conclusions: In patients with PAD, diabetic men and women with CAD had more severe claudication than
their non-diabetic counterparts, as measured by shorter PWT, and the men had further ambulatory im-
pairment manifested by slower 4-meter gait speed. Furthermore, the diabetic patients with CAD had
elevations in interleukin-8, leptin, and PEDF.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
PAD is a signiﬁcant medical concern, as it is a highly prevalent
[1], costly [2], disabling [3,4], and deadly condition [5]. Exercise
therapy is a primary treatment for patients with PAD, as the COT,
PWT, and 6-minute walk distance increase following a program of
exercise rehabilitation [6–9]. However, the response to a program
of exercise rehabilitation is variable, as we recently found that di-
abetic women responded poorly to a program of exercise compared
to other subgroups of patients despite no difference in exercise ad-
herence [10].
The relatively poor exercise response in diabetic women with
PADmay be due to several possible factors.We have previously found
that women have greater impairment in ambulation [11] and vas-
cular function [12] compared tomen. Furthermore, we recently found
that women have greater inﬂammation than men [13], and that in-
ﬂammation and anti-oxidant capacity were predictors of COT, PWT,
and calf muscle hemoglobin oxygen saturation during exercise [14].
Abbreviations: ABI, ankle/brachial index; COT, claudication onset time; HsCRP,
high sensitivity C-reactive protein; NF-κB, nuclear factor K-light-chain-enhancer of
activated B cells; PAD, peripheral artery disease; PEDF, pigment epithelium-
derived factor; PWT, peak walking time; ROS, reactive oxygen species
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In addition to sex differences in ambulation and inﬂammation, di-
abetes has been found to impair ambulation in several [15,16], but
not in all studies [17]. Diabetes may differentially impact women
and men with PAD, but little is known about the sex-speciﬁc effect
of diabetes on ambulatory and inﬂammatory proﬁles in patients with
symptomatic PAD.
The primary aim of the current study was to determine whether
diabetes and sex were factors associated with ambulatory func-
tion, endothelial cell inﬂammation, oxidative stress, and apoptosis,
and with circulating biomarkers of inﬂammation and antioxidant
capacity in patients with PAD and claudication. We hypothesized
that patients with diabetes have impaired ambulation, greater en-
dothelial inﬂammation, cellular ROS production, and apoptosis, and
worse circulating inﬂammatory biomarkers and antioxidant capac-
ity than those without diabetes. Furthermore, we hypothesized that
the negative impact of diabetes on these outcomemeasures aremore
prominent in women than in men.
Methods
Patients
Approval and informed consent
The institutional review board at the University of Oklahoma
Health Sciences Center approved the procedures of this study.
Written informed consent was obtained from each patient at the
beginning of investigation.
Recruitment
Patients who were not currently exercising were recruited from
vascular laboratories and vascular clinics from the University of Okla-
homa Health Science Center for possible enrollment into an exercise
rehabilitation program to treat leg pain secondary to PAD.
Baseline clinical characteristics obtained from a medical history and
physical examination
Patients were evaluated in the morning at the Clinical Re-
search Center, at the University of Oklahoma Health Science Center.
Patients arrived fasted, but were permitted to take their usual medi-
cations. To begin the study visit, patients were evaluated with a
medical history and physical examination in which demographic
information, height, weight, waist circumference, cardiovascular risk
factors, co-morbid conditions, claudication history, ABI, and a list
of current medications were obtained. Following the medical
history and physical examination, nursing personnel obtained blood
samples, and exercise personnel performed the exercise tests. The
nursing and exercise personnel were blinded to the results from the
medical history and physical examination, including the diabetes
status of the patients.
Inclusion and exclusion criteria
Patients with symptomatic PAD were included in this study if
they met the following criteria: (a) a history of ambulatory leg pain,
(b) ambulatory leg pain conﬁrmed by treadmill exercise [3], and (c)
an ABI ≤ 0.90 [18] at rest or ≤0.73 after exercise [19]. Patients were
excluded for the following conditions: (a) absence of PAD (ABI > 0.90
at rest and ABI > 0.73 after exercise), (b) non-compressible vessels
(ABI ≥ 1.40), (c) asymptomatic PAD, (d) use of medications indi-
cated for the treatment of claudication (cilostazol or pentoxifylline)
initiated within three months prior to investigation, (e) exercise
limited by other diseases or conditions, (f) active cancer, (g) end stage
renal disease deﬁned as stage 5 chronic kidney disease, and (h) ab-
normal liver function. A consecutive series of 268 individuals were
evaluated for eligibility, and 180 patients were deemed eligible for
inclusion into the study.
Patients were grouped according to their diabetes status and sex.
Diabetes was conﬁrmed through medical history and list of medi-
cations, or by a glucose value of greater than or equal to 126 mg/
dl in those patients without history or medication for diabetes. All
patients with diabetes had Type 2 diabetes.
Measurements
COT and PWT obtained from a graded maximal treadmill test
Patients performed a graded treadmill test to determine study
eligibility, and then repeated the test on a following visit within one
week to obtain the primary outcome measures of COT and PWT as
previously described [3,6]. Using our procedures, the test-retest
intraclass reliability coeﬃcient is R = 0.89 for COT [3] and R = 0.93
for PWT [3].
Total walk distance obtained from a 6-minute walk test
Patients performed an over-ground, 6-minute walk test super-
vised by trained exercise technicians, as previously described from
our laboratory [20]. The total distance walked during the test was
recorded. The test-retest intraclass reliability coeﬃcient is R = 0.94
for total 6-minute walking distance [20].
Gait speed obtained from a 4-meter walk test
Gait speed was measured from a 4-meter walk test in a hallway
[21]. Patients performed this test twice at their usual walking pace,
and the faster of the two walks was used in the analyses. The test-
retest intraclass reliability coeﬃcient is R = 0.96 for the velocity to
walk four meters [22].
Blood sampling
Blood was drawn by venipuncture from an antecubital vein, col-
lected in vacutainers, and distributed in 0.5ml aliquots. The samples
were stored at −80 °C, and were subsequently batched for analysis.
Endothelial cell cultures
A cell culture-based bioassay approach utilizing cultured primary
human arterial endothelial cells was used to characterize the en-
dothelial effects of circulating factors present in the sera of patients.
In brief, endothelial cells (purchased from Cell Applications, Inc., San
Diego, CA, after passage 4; age of the donors is unknown) were ini-
tially cultured in MesoEndo Endothelial Cell Growth Medium (Cell
Applications, Inc.) followed by Endothelial Basal Medium supple-
mented with 10% fetal calf serum until the time of serum treatment,
as described [23]. Inter-individual variance is unlikely to contrib-
ute to observed differences because detector cells used for each in
vitro studywere from the same donor. For treatment, fetal calf serum
was replaced with serum (10%; for 24–48 h) collected from our pa-
tients [23]. Cells cultured in Endothelial Basal Medium supplemented
with 10% fetal calf serum served as an additional control.
Apoptosis assay
Cultured endothelial cells were treated with sera from patients
for 24 hours. Caspase activities using Caspase-Glo 3/7 assay kit
(Promega, Madison, WI) were measured to assess apoptotic cell
death, as previously reported [23].
Cellular ROS production
Hydrogen peroxide production in detector endothelial cells was
measured ﬂuorometrically using the Amplex Red/horseradish per-
oxidase assay to determine cellular oxidative stress induced by factors
present in the sera [23].
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Transient transfection, NF-κB reporter gene assay
Transcriptional activity of NF-κB was tested in serum-treated de-
tector endothelial cells by a reporter gene assay, to determine cellular
pro-inﬂammatory effects induced by factors in the sera [23]. Trans-
fections in endothelial cells were performed using the Amaxa
Nucleofector technology (Amaxa, Gaithersburg, MD), as we have pre-
viously reported [23].
Serum antioxidant capacity
Hydroxyl radical antioxidant capacity using the OxiSelect hy-
droxyl radical antioxidant capacity activity assay (Cell Biolabs Inc.,
San Diego, CA) was measured from sera to determine the capacity
of antioxidant enzymes and other redox molecules to counterbal-
ance the deleterious effects of oxidative stress in the sera of patients
[23].
Circulating inﬂammatory and vascular biomarkers
A Milliplex Human Adipokine Magnetic Bead Kit was used for
determining tumor necrosis factor alpha, interleukin-6, interleukin-
8, leptin, and insulin. AMilliplex Human Cardiovascular Disease Panel
1 Kit was used for E selectin and vascular cell adhesion molecule-
1. These assays were performed according to manufacturer’s
protocols. Sample protein content was determined for normaliza-
tion purposes by a spectrophotometric quantiﬁcation method using
BCA reagent (Pierce Chemical Co., Rockford, IL).
HsCRP
Concentration of HsCRP was quantiﬁed from 300 μl of sera using
a high-sensitivity Near Infrared Particles Immunoassay. The
SYNCHRON LX-20 (Beckman-Coulter, California, USA), a commer-
cially available device, was used to perform the assay. Prior to
performing each assay, the SYNCHRON system was calibrated, and
a calibration curve was established [24].
PEDF
Plasma PEDF was measured using an ELISA kit from Millipore
(#CYT420, St. Charles, MO) as described previously [25]. Brieﬂy,
plasma samples were incubated with 8 mol/l urea (Sigma Aldrich)
at room temperature for 1 h and diluted 1:400. Samples were then
applied in duplicate onto an antibody-coated plate and incubated
at 37 °C for 1 h. After extensive wash, the plate was incubated with
biotinylatedmouse anti-PEDF antibody, followed by incubation with
streptavidin peroxidase conjugate. After addition of 3,3′,5,5′-
tetramethylbenzidine, the plate was read (450 nm) by a Wallac-
Victor3 1420 microplate reader. Intra and inter-assay coeﬃcient of
variations were 5.6 and 9.0% respectively.
Statistical analyses
Preliminary analysis revealed that coronary artery disease (CAD)
prevalence in diabetic men (53%) compared to prevalence in non-
diabetic men (25%) was signiﬁcant (p = 0.007), Similarly, the
prevalence in diabetic women (39%) compared to prevalence in non-
diabetic women (15%} was also signiﬁcant (p = 0.015). To assure that
this difference did not inﬂuence planned comparisons, the data set
was partitioned into CAD positive and CAD negative strata. Within
each stratum clinical characteristics were summarized for diabet-
ic and non-diabetic patients within sex. Summary statistics for
measurement variables were means and standard deviations and
percent of patients with characteristics present for dichotomous vari-
ables. Differences between sexes for measurement variables were
examined using a 2 sample t-test. Between-sex differences for di-
chotomous variables were examined using a 1 degree of freedom
chi-square test or Fischer exact test. Within each of the four diabetic/
sex groups, the distributions for both the physical performances and
other response variables displayed appreciable departure from the
normal distribution. Therefore, these variables were summarized
as medians and inter-quartile ranges. TheWilcoxon non-parametric
procedure was used to examine difference in medians for diabetic
and non-diabetic patients within each sex within each stratum. The
Wilcoxon test and Spearman correlation yield the same p-value for
a dichotomous classiﬁcation and a response variable. Hence, the
partial Spearman controlled for other variables may be used as a
non-parametric analog for the parametric ANCOVA to adjust p-
values for extraneous variables. The p-value for partial Spearman
correlation controlled for any adjusting variables is reported as ad-
justed p-value for comparisons between diabetic groups. As a guard
against over parameterization, adjustments were made only for ex-
traneous variables exhibiting statistical signiﬁcance between groups.
Variables such as obesity, BMI, etc. which reﬂect well recognized
characteristics associated with diabetics were not regarded as ex-
traneous variables and no adjustment was made for them, lest the
adjustment reduce the effect of diabetes. All computations were
made with the NCSS 2004 computer package. Statistical signiﬁ-
cance was deﬁned as p < 0.05.
Results
The clinical characteristics of the patients are shown in Table 1.
Compared to men without diabetes, men with diabetes had higher
prevalence of obesity (p < 0.001), abdominal obesity (p < 0.001), met-
abolic syndrome (p < 0.05), dyslipidemia (p < 0.05), and coronary
artery disease (p < 0.01), and they had higher BMI (p < 0.001) and
greater number of metabolic syndrome components (p < 0.001).
Compared to women without diabetes, women with diabetes had
higher prevalence of obesity (p < 0.001), abdominal obesity
(p < 0.001), metabolic syndrome (p < 0.001), coronary artery disease
(p < 0.05), and they had higher BMI (p < 0.001), greater number of
metabolic syndrome components (p < 0.001), lower age (p < 0.01),
and lower percentage of Caucasians (p < 0.05).
The exercise measurements of the patients are displayed in
Table 2. On average, diabetic men with CAD had a lower median
PWT of 234 seconds compared to non-diabetic men with CAD
(p < 0.05), and diabetic women with CAD had a lower median PWT
of 272 seconds compared to their non-diabetic counterparts
(p < 0.01). Additionally, the diabetic men with CAD had a slower
median 4-meter gait speed of 0.21 meters/second than non-
diabetic men with CAD (p < 0.05). No other group differences
(p > 0.05) were found in the men and women.
The vascular biomarkers of the patients are shown in Table 3.
Diabetic men with CAD had higher median PEDF (p < 0.05) and
insulin levels (p < 0.05) than their non-diabetic counterparts. Ad-
ditionally, diabetic women with CAD had higher median leptin
(p < 0.01) and interleukin-8 levels (p < 0.05) than non-diabetic
women with CAD. No other group differences (p > 0.05) were found
in the patients.
Discussion
One novel ﬁnding was that diabetic men with CAD had im-
paired ambulation compared to their non-diabetic counterparts,
as measured by a lower PWT and a slower 4-meter gait speed.
Similarly, the diabetic women with CAD had lower PWT than non-
diabetic women with CAD. Another novel ﬁnding was that
diabetic men with CAD had higher PEDF than non-diabetic men,
and that diabetic women with CAD had greater inﬂammation than
women free of diabetes, as measured by elevated interleukin-8 and
leptin.
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Diabetes and impaired ambulation
Men andwomenwith diabetes and concomitant CADwalked 234
and 272 fewer seconds during the graded maximal treadmill test
than those with diabetes, indicating that they reachedmaximal clau-
dication at a much lower exercise capacity. For example, the diabetic
men with CAD reached a median ﬁnal work stage of 4% grade, while
those without diabetes walked to 8% grade, and in women the re-
spective values were 2% and 6%. These data indicate that diabetic
patients with CAD have more severe claudication and greater am-
bulatory impairment than those who are free of diabetes. These
observations support our previous report that patients with PAD
and metabolic syndrome, a condition that often precedes diabe-
tes, had shorter mean distances to the onset and to maximal
claudication pain, respectively [26].
The lower PWT during the treadmill test in patients with dia-
betes and CAD is also of interest because the lower exercise capacity
may potentially limit their daily ambulatory activities that are above
minimal exercise intensities. This is evident with the 4-meter walk
test, as they had an 18% slower gait speed than men without dia-
betes, which supports a previous study that found that PAD patients
with diabetes had slower 4-meter walking speed than patients
without diabetes [15]. The slower gait speed over four meters in
the current study would project to 75 fewer meters covered during
a 6-minute walk test, which would represent a large and clinically
meaningful difference between the groups [27]. In fact, the actual
Table 1
Clinical characteristics of patients with peripheral artery disease. Values are means (SD) and percentages.
Variables Diabetic men
(n = 36)
Non-diabetic
men (n = 59)
Diabetic women
(n = 39)
Non-diabetic
women (n = 46)
Age (years) 66 (9) 67 (10) 61 (7)† 67 (12)
Body mass index (kg/m2) 31.8 (6.0)‡ 27.0 (4.4) 32.2 (5.7)‡ 26.9 (6.7)
Rest ankle/brachial index 0.75 (0.25) 0.70 (0.20) 0.66 (0.27) 0.70 (0.23)
Post-exercise ankle/brachial index 0.45 (0.33) 0.40 (0.28) 0.41 (0.32) 0.47 (0.34)
Race (% Caucasian) 58 68 51† 65
Current smoking (% yes) 36 34 36 47
Hypertension (% yes) 92 85 95 80
Medication use (% yes) 88 92 97 89
Number of medications (n) 2.8 2.1 2.3 2.2
Dyslipidemia (% yes) 92* 73 85 85
Medication use (% yes) 88 81 91 82
Statin use (% yes) 79 77 73 69
Number of medications (n) 1.3 1.2 1.1 1.3
Other medications
Aspirin use (% yes) 64 71 64 57
Plavix use (% yes) 25 19 33 15
Abdominal obesity (% yes) 69
‡
34 82‡ 39
Metabolic syndrome (% yes) 92* 73 100‡ 65
Metabolic syndrome components (n) 4.4‡ 2.8 4.6‡ 2.7
Obesity (% yes) 64‡ 25 62† 28
Lower extremity revascularization (% yes) 31 24 36 39
Coronary artery disease (% yes) 53† 25 38* 15
Cerebrovascular disease (% yes) 8 19 15 17
Chronic kidney disease (% yes) 29 26 21 28
Chronic obstructive pulmonary disease (% yes) 14 27 38 30
Dyspnea (% yes) 53 49 77 65
Arthritis (% yes) 58 54 59 72
* Signiﬁcantly different than non-diabetic group (p < 0.05).
† p < 0.01.
‡ p < 0.001.
Table 2
Exercise measures of patients with peripheral artery disease. Values are medians (interquartile ranges).
Variables Diabetic men
(n = 36)
Non-diabetic
men (n = 59)
Diabetic women
(n = 39)
Non-diabetic
women (n = 46)
Claudication onset time (s)
CAD 120 (145) 165 (219) 107 (71) 107 (101)
No CAD 120 (93) 160 (232) 121 (115) 118 (168)
Peak walking time (s)
CAD 281 (206)* 515 (393) 192 (140)† 464 (343)
No CAD 389 (347) 449 (393) 294 (331) 268 (299)
6-minute walk distance (m)
CAD 321 (117) 383 (110) 244 (172) 368 (140)
No CAD 410 (44) 417 (94) 335 (1910) 349 (133)
Gait speed (m/s)
CAD 0.99 (0.16)† 1.20 (0.24) 0.95 (0.29) 0.99 (0.08)
No CAD 1.05 (0.30) 1.08 (0.29) 1.03 (0.35) 0.98 (0.26)
Data for the women were adjusted for age and race.
* Signiﬁcantly different than non-diabetic group (p < 0.05).
† p < 0.01.
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mean 6-minute walk distance of the diabetic men and women with
CAD were 62 and 124 meters shorter than their non-diabetic coun-
terparts, but these trends did not reach statistical signiﬁcance.
A ﬁnal interesting observation was that the impact of diabetes
on PWT and gait speed was found in those with concomitant CAD,
but not in patients free of CAD, suggesting that diabetes and CAD
work synergistically to impair ambulation. This ﬁnding supports a
previous observation from our laboratory that patients with CAD
and stable angina have worse ambulation than in those without CAD
during a longer 6-minute walk test that requires endurance, a shorter
4-meter walk test that is representative of typical daily ambulation
at a usual preferred pace, and in patient-perceived ability to walk
at various distances and speeds, and to climb stairs [28]. It is not
clear why the combination of having diabetes and CAD is a partic-
ularly troublesome combination for ambulation in patients with PAD,
but it may be that diabetes has peripheral effects and complica-
tions that impair lower extremity functioning [15,16], and CAD has
central effects that impair aerobic ﬁtness [29,30] as well as periph-
eral effects that impair muscular strength, endurance, and motor
unit recruitment [31,32].
Diabetes and inﬂammation
The primary ﬁndings related to the inﬂammatory proﬁles of the
current study was that diabetic women with CAD had greater levels
of interleukin-8 and leptin than women free of diabetes, and dia-
betic men with CAD had greater levels of PEDF than in their non-
diabetic counterparts. We have recently found that womenwith PAD
have higher inﬂammation than men with PAD, and that race was
a factor in explaining the sex-related differences in inﬂammation
[13]. Thus, the present investigation extends these ﬁndings by
showing that diabetes, in the presence of CAD, is another factor con-
tributing to elevated inﬂammation in symptomatic patients with
PAD. The higher levels of these inﬂammatory biomarkers in dia-
betic patients with CAD may partially explain why diabetes is a
strong risk factor for PAD [33], and why those with diabetes rep-
resent a subgroup of patients with PAD who are more susceptible
to progression of atherosclerosis [34], and increased risk of coro-
nary events [34]. A noteworthy ﬁnding was that diabetic women
with CAD had nearly a 6-fold higher leptin level than non-diabetic
women. High levels of leptin are indicative of leptin resistance, which
Table 3
Inﬂammatory and vascular biomarkers of patients with peripheral artery disease. Values are medians (interquartile ranges).
Variables Diabetic men
(n = 36)
Non-diabetic
men (n = 59)
Diabetic
women (n = 39)
Non-diabetic
women (n = 46)
Apoptosis (AU)
CAD 1.03 (0.40) 1.05 (0.25) 0.83 (1.09) 1.08 (0.22)
No CAD 1.05 (0.32) 1.21 (0.21) 1.01 (0.47) 1.02 (0.51)
Cellular ROS production (AU)
CAD 24.58 (9.34) 28.73 (11.77) 20.37 (8.22) 29.07 (14.28)
No CAD 28.19 (6.10) 26.15 (7.09) 28.22 (4.50) 25.12 (5.56)
NF-κB activity (AU)
CAD 1.11 (0.91) 1.40 (0.62) 0.82 (1.38) 1.25 (1.04)
No CAD 1.43 (0.99) 0.98 (1.10) 0.88 (0.97) 1.46 (0.99)
High sensitivity C-reactive protein (mg/L)
CAD 3.78 (3.99) 2.40 (5.20) 3.80 (6.00) 3.30 (3.56)
No CAD 3.30 (2.31) 3.55 (4.89) 6.70 (5.90) 2.80 (5.30)
Tumor necrosis factor alpha (pg/ml)
CAD 44 (14) 64 (26) 57 (32) 48 (34)
No CAD 59 (41) 45 (27) 49 (28) 48 (31)
Interleukin-6 (pg/ml)
CAD 21 (26) 23 (6) 26 (20) 23 (14)
No CAD 26 (23) 27 (14) 24 (16) 21 (10)
Interleukin-8 (pg/ml)
CAD 87 (45) 90 (61) 119 (37)* 76 (31)
No CAD 99 (47) 85 (49) 93 (89) 95 (55)
E selectin (pg/ml)
CAD 44 (28) 27 (27) 38 (22) 34 (19)
No CAD 51 (68) 36 (25) 72 (62) 32 (37)
Vascular cell adhesion molecule-1 (pg/ml)
CAD 2173 (1023) 2110 (1804) 1967 (813) 2732 (1190)
No CAD 1894 (886) 2060 (695) 2133 (1084) 2099 (759)
Leptin (pg/ml)
CAD 2025 (1870) 1079 (2123) 4202 (1601)† 719 (3443)
No CAD 1665 (1677) 755 (862) 3459 (5184) 1889 (1988)
Pigment epithelium-derived factor (ng/ml)
CAD 7941 (2184)* 3168 (1809) 8561 (5861) 11770 (0)
No CAD 7046 (5903) 5835 (3047) 10456 (6374) 5880 (4350)
Hydroxyl radical antioxidant capacity (AU)
CAD 0.86 (0.29) 0.93 (0.39) 0.94 (0.29) 0.98 (0.19)
No CAD 0.90 (0.29) 0.93 (0.22) 0.93 (0.18) 0.92 (0.29)
Insulin (μIU/ml)
CAD 10.4 (6.6)* 7.2 (12.0) 10.0 (10.7) 6.7 (16.9)
No CAD 9.2 (10.9) 6.9 (6.9) 10.1 (9.4) 4.5 (8.2)
AU = arbitrary units, ROS = reactive oxygen species.
Data for the women were adjusted for age and race.
* Signiﬁcantly different than non-diabetic group (p < 0.05).
† p < 0.01.
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may be an interface between inﬂammation and metabolism in
obesity-related cardiovascular disease [35]. From a physical func-
tion standpoint, higher inﬂammation associated with diabetes may
increase the risk of impaired ambulatory ability, as higher inﬂam-
mation is associated with skeletal muscle protein breakdown [36],
lower muscle mass [37], lower strength [37], worse functional per-
formance [38], greater apoptosis in skeletal myocytes [39], higher
percentage of fat within the calf muscle [37], and a greater decline
in function during longitudinal follow-up [40].
A ﬁnal interesting observation is that PEDF was higher in dia-
betic men with CAD than in their non-diabetic counterparts. PEDF
is a neurotrophic factor secreted by adipocytes and hepatocytes with
a variety of functions, one of which includes potent angiogenic in-
hibition [41]. PEDF inhibits endothelial cell migration [41], reduces
endothelial proliferation [42], increases apoptosis of endothelial cells
[43], and downregulates vascular endothelial growth factor [44].
Thus, higher levels of PEDF in the men with diabetes may further
impair the already compromised circulation in the lower extremi-
ties secondary to PAD.
Limitations
There are limitations to this study. A self-selection bias may exist
regarding study participation, as patients who participated in this
trial were volunteers. Therefore, theymay represent those whowere
more interested in participation, who had better access to trans-
portation to the research center, andwho had relatively better health
than patients who did not volunteer. Furthermore, the results of this
study are only applicable to symptomatic patients with PAD, and
may not be generalized to asymptomatic patients and patients with
more severe forms of PAD, such as critical limb ischemia. An addi-
tional limitation is that we did not measure the duration of having
diabetes or the hemoglobin A1c levels, and thus do not have an es-
timate of long-term inﬂuence and control of diabetes. However, we
believe the patients with diabetes were well-controlled prior to en-
tering the study because most were taking medications, and no
patient had glucose values, indicating that they were metaboli-
cally out of control. Another limitation is that it is diﬃcult to separate
the effects of obesity from diabetes on the outcome measures
because of the close connection between the two. All of the pa-
tients with diabetes were either overweight or obese, and thus
adjusting for obesity-related variables is essentially adjusting for
diabetes in these groups of patients with PAD. Finally, there are limi-
tations associatedwith the design of the study. Signiﬁcant differences
in ambulation and inﬂammation between diabetic and non-
diabetic groups within each sex do not provide evidence of causality.
Although these limitations exist, we believe that the ﬁndings of the
present study are generalizable to the large number of symptom-
atic patients with PAD because the sample is racially mixed, and
has a high prevalence of typical risk factors for PAD such as
dyslipidemia, hypertension, obesity, and smoking.
Conclusion and clinical signiﬁcance
In patients with PAD, diabetic men and women with CAD had
more severe claudication than their non-diabetic counterparts, as
measured by shorter PWT, and the men had further ambulatory im-
pairment manifested by slower 4-meter gait speed. Furthermore,
the diabetic patients with CAD had elevations in interleukin-8, leptin,
and PEDF. The primary clinical implication is that diabetic pa-
tients with CAD represent a subgroup of PAD patients who have
particularly poor ambulatory function, and therefore should be high
priority for targeted exercise therapy and dietary intervention to
improve both ambulation and inﬂammatory proﬁles.
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